Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19.
Drug Des Devel Ther
; 14: 3995-4001, 2020.
Article
in English
| MEDLINE | ID: covidwho-836051
ABSTRACT
The coronavirus disease 2019 (COVID-19) global pandemic continues and antiviral agents and vaccines are currently under investigation. Mesenchymal stem cell (MSC)-based therapy can be a suitable option for management of patients with COVID-19 at the urgent time of virus outbreak. Currently, MSCs are being explored against the novel infectious disease due to their therapeutic properties of anti-inflammation, immunomodulation and tissue repair and regeneration, albeit the precise mechanisms of MSC action toward COVID-19 remain unclear. To date, rigorous results from clinical trials using MSCs in human have been weakly positive. The pervasive uncertainty of using MSC therapeutic products as an effective combatant against COVID-19 requires rigorous resolution on several fronts, including MSC fate after infusion, safety issue, homing capability, and MSC resistance to the disease microenvironment. Focusing on these facets, a few important ones will be critically analyzed and addressed in this article for the development of safe and effective MSC-based therapies for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Mesenchymal Stem Cell Transplantation
/
Betacoronavirus
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Drug Des Devel Ther
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS